Page last updated: 2024-11-13
rb 150
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
firibastat: has antihypertensive activity; a dimer of EC33 with a disulfide linkage; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24851355 |
| CHEMBL ID | 4297511 |
| SCHEMBL ID | 1694944 |
| MeSH ID | M0521044 |
Synonyms (30)
| Synonym |
|---|
| 648927-86-0 |
| firibastat |
| AKOS022180293 |
| SCHEMBL1694944 |
| rb-150 |
| firibastat [inn] |
| 638KY4573I , |
| qgc-001 |
| qgc001 |
| firibastat [who-dd] |
| (3s,3s')-4,4'-disulfanediylbis(3-aminobutane-1-sulfonic acid) |
| 1-butanesulfonic acid, 4,4'-dithiobis(3-amino-, (3s,3's)- |
| qgc 001 |
| (3s,3's)-4,4'-dithiobis(3-aminobutane-1-sulfonic acid) |
| 4,4'-dithio(bis(3-aminobutyl sulfonic acid)) |
| unii-638ky4573i |
| rb 150 |
| rb150 |
| CS-0032985 |
| HY-109058 |
| DB13107 |
| (s)-3-amino-4-(((s)-2-amino-4-sulfobutyl)disulfaneyl)butane-1-sulfonic acid |
| qgc001;rb150 |
| 1601301-49-8 |
| Q27263587 |
| CHEMBL4297511 |
| MS-25919 |
| (3s,3's)-4,4'-disulfanediylbis(3-aminobutane-1-sulfonicacid) |
| GLXC-25368 |
| (3s)-3-amino-4-[[(2s)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "We conducted a pilot multicenter double-blind randomized placebo-controlled crossover pharmacodynamic study to evaluate the blood pressure (BP) and the hormonal effects of firibastat, a first-in-class aminopeptidase A inhibitor prodrug, in patients with hypertension." | ( A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension. Amar, L; Azizi, M; Balavoine, F; Courand, PY; De Mota, N; Delsart, P; Denolle, T; Lantelme, P; Llorens-Cortes, C; Mounier-Vehier, C; Zhygalina, V, 2019) | 0.51 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers." | ( Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats. Balavoine, F; De Mota, N; Hmazzou, R; Llorens-Cortes, C; Marc, Y, 2021) | 0.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150." | ( Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Balavoine, F; Bodineau, L; Fassot, C; Frugière, A; Inguimbert, N; Llorens-Cortes, C; Marc, Y; Roques, B, 2008) | 0.35 |
| " Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain." | ( Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Balavoine, F; Gao, J; Llorens-Cortes, C; Marc, Y; Michaud, A; Roques, BP, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 64.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (64.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (11.11%) | 5.53% |
| Reviews | 7 (38.89%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||